Futibatinib for advanced bile duct cancer with FGFR2 changes
Part of Cancer clinical trials.
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have bile duct cancer that cannot be fully removed or has spread (intrahepatic or extrahepatic).
- Your tumor test must show an FGFR2 gene fusion or rearrangement.
- You must have already tried at least one gemcitabine + platinum chemotherapy treatment.
- Your scans must show the cancer got worse after the most recent treatment.
- You must have measurable tumors on imaging and be able to do normal daily activities (performance status 0 or 1).
- Your body organs (blood, liver, kidneys) must be strong enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
This study tests a new oral medication (tinengotinib) against standard chemotherapy for people with advanced bile duct cancer that has a specific gene change (FGFR2). Doctors want to see if this drug can help shrink or slow the cancer better than current treatments.
This trial tests a new targeted therapy, futibatinib, for people with advanced or unresectable bile duct cancer who have not had prior treatment for advanced disease. It aims to see if this drug can help shrink or control the cancer.
This trial tests a new combination of drugs (futibatinib plus chemo-immunotherapy) for people with advanced colorectal cancer who have not had prior treatment. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a pill called pemigatinib for people with bile duct cancer that has spread and has a specific gene change (FGFR2 fusion or rearrangement). It may slow or stop tumor growth. The study is for those whose cancer has progressed after at least one prior treatment.
This trial tests whether giving a targeted medicine based on your tumor's genetic makeup, after surgery, can help prevent your bile duct or gallbladder cancer from coming back. It's a new approach that tries to match treatment to your specific cancer biology.
Hear when a new Advanced Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.